Why Is Small-Cap Cancer Focused Vincerx Pharma Stock Plummeting On Tuesday?
Why Is Small-Cap Cancer Focused Vincerx Pharma Stock Plummeting On Tuesday?
On Monday, Vincerx Pharma Inc (NASDAQ:VINC) presented preliminary Phase 1 data for VIP236 and updates on pipeline progress at the American Association for Cancer Research Annual Meeting 2024.
週一，Vincerx Pharma Inc（納斯達克股票代碼：VINC）在美國癌症研究協會2024年年會上公佈了 VIP236 的初步第一階段數據和研發進展的最新情況。
VNC-236-101 is a Phase 1 dose-escalation study with monotherapy VIP236 for metastatic tumor patients who have exhausted all standard therapy options.
VNC-236-101 是一項 1 期劑量遞增研究，採用單一療法 VIP236，適用於已用盡所有標準療法的轉移性腫瘤患者。
- Fifteen patients have been dosed to date on the once-every-three-weeks (Q3W) schedule:
- The Q3W schedule is well tolerated with no dose-limiting toxicity (DLT) in any patients, and no patients have discontinued VIP236 due to an adverse event.
- No severe or life-threatening diarrhea has been observed, validating the purposeful design of VIP236's optimized camptothecin payload.
- Seven patients have achieved objective stable disease, including tumor reduction. Four patients remain on the study, with the longest-treated patient for 168 days.
- 迄今爲止，已按照每三週一次（Q3W）的時間表給15名患者服藥：
- Q3W 計劃耐受性良好，對任何患者均無劑量限制毒性 (DLT)，也沒有患者因不良事件停藥 VIP236。
- 沒有觀察到嚴重或危及生命的腹瀉，這驗證了 VIP236 優化的喜樹鹼有效載荷的有針對性的設計。
- 七名患者實現了客觀穩定的疾病，包括腫瘤減少症。四名患者仍在研究中，接受治療時間最長的患者爲168天。
VNC-943-101 is a Phase 1 dose-escalation study with monotherapy VIP943 for CD123+ acute myeloid leukemia, B-cell acute lymphocytic leukemia, or myelodysplastic syndromes.
VNC-943-101 是一項 1 期劑量遞增研究，採用單一療法 VIP943 治療 CD123+ 急性髓系白血病、B 細胞急性淋巴細胞白血病或骨髓增生異常綜合徵。
- VIP943 is administered once per week.
- No DLTs occurred in Cohort 1 and 2. Four patients have been enrolled in Cohort 3 (0.7 mg/kg) and are undergoing DLT assessment.
- VIP943 PK data shows very little free payload in circulation, consistent with the favorable safety profile observed preclinically and clinically.
- VIP943 每週給藥一次。
- 隊列 1 和 2 中未發生 DLT。四名患者已加入隊列3（0.7 mg/kg），並正在接受DLT評估。
- VIP943 PK數據顯示，流通中的自由有效載荷很少，這與臨床前和臨床觀察到的良好安全性相一致。
Vincerx will present additional Phase 1 data for VIP236 and VIP943 on or around the 2024 European Hematology Association Annual Meeting in June 2024.
Vincerx 將在 2024 年 6 月的 2024 年歐洲血液學協會年會上或前後公佈 VIP236 和 VIP943 的其他 1 期數據。
Vincerx also reported preclinical experiments applying the next-generation effector chemistry of its VersAptx platform to the antibodies of approved antibody-drug conjugates (ADCs), Trodelvy and Enhertu, demonstrating the potential to improve tumor toxicity of ADCs by orders of magnitude.
Vincerx還報告了將其VersaptX平台的下一代效應化學應用於已批准的抗體藥物偶聯物（ADC）Trodelvy和Enhertu的抗體的臨床前實驗，表明ADC的腫瘤毒性有可能提高几個數量級。
- In in vitro tumor models, Vincerx's sacituzumab-legumain-KSPi ADC had a 20-fold improvement in tumor toxicity compared with Trodelvy (sacituzumab-govitecan).
- The company's trastuzumab-legumain-KSPi ADC demonstrated an 8-fold increase in tumor toxicity compared with Enhertu (fam-trastuzumab-deruxtecan).
- 在體外腫瘤模型中，與Trodelvy（sacituzumab-govitecan）相比，Vincerx的Sacituzumab-Legumain-KSPI ADC的腫瘤毒性提高了20倍。
- 該公司的Trastuzumab-Legumain-KSPI ADC顯示，與Enhertu（fam-trastuzumab-deruxtecan）相比，腫瘤毒性增加了8倍。
Price Action: VINC shares are down 73.30% at $1.27 on the last check Tuesday.
價格走勢：在週二的最後一次支票中，VINC股價下跌73.30％，至1.27美元。
Photo via Shutterstock
照片來自 Shutterstock
譯文內容由第三人軟體翻譯。